Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-25-107128
Filing Date
2025-04-30
Accepted
2025-04-30 16:05:27
Documents
18
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d935413d10ka.htm   iXBRL 10-K/A 473363
2 EX-31.3 d935413dex313.htm EX-31.3 3711
3 EX-31.4 d935413dex314.htm EX-31.4 3702
  Complete submission text file 0001193125-25-107128.txt   894245

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rgls-20241231.xsd EX-101.SCH 5919
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rgls-20241231_def.xml EX-101.DEF 2934
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20241231_lab.xml EX-101.LAB 23550
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20241231_pre.xml EX-101.PRE 18855
21 EXTRACTED XBRL INSTANCE DOCUMENT d935413d10ka_htm.xml XML 31605
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

EIN.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-35670 | Film No.: 25894925
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)